This study is not yet accepting patients

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

a study on Psoriasis Atopic Dermatitis (Eczema)

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
study ends around
Principal Investigator
by Raymond Cho, MD, PhD
Headshot of Raymond Cho
Raymond Cho

Description

Summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Official Title

Utilization of a Cutaneous Therapy In Situ Microdevice

Keywords

Psoriasis, Atopic Dermatitis, Triamcinolone, Fluorouracil, calcipotriene, tapinarof, crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab Pegol, Infliximab, secukinumab, ixekizumab, apremilast, risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolic Acid, Azathioprine, Chloroquine, Cyclosporine, tofacitinib, deucravacitinib, dupilumab, tralokinumab, guselkumab, tildrakizumab, abrocitinib, upadacitinib, lebrikizumab, nemolizumab, ruxolitinib, bimekizumab, Roflumilast, In situ cutaneous microdevice, 5-Fluorouracil, Certolizumab, Mycophenolate, Baractinib

Eligibility

You can join if…

Open to people ages 18 years and up

> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days)

You CAN'T join if...

None

Location

  • UCSF
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Raymond Cho, MD, PhD
    Dr. Cho is a physician and geneticist who investigates the molecular basis of skin disease. With colleague Dr. Jeffrey Cheng, he co-directs the RashX initiative at UCSF, which develops precision transcriptomic biomarkers redefining canonical rash types. The ultimate goal of this project is to fingerprint and treat unusual cases of cutaneous inflammation.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT07352566
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 10 study participants
Last Updated